As Propagermanium moves closer to clinical approval, what is the likelihood that the drug will be approved?

Propagermanium is under clinical development by Dimerix and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Propagermanium’s likelihood of approval (LoA) and phase transition for Diabetic Nephropathy took place on 03 Feb 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Propagermanium Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Propagermanium overview

Propagermanium (DMX-200) as an adjunct therapy with irbesartan is under development for the treatment of chronic kidney disease (CKD) associated proteinuria, focal segmental glomerulosclerosis (FSGS) and COVID -19 pneumonia. It is administered through oral and nasogastric route. Propagermanium acts by targeting chemokine (C-C motif) receptor 2. The drug candidate is developed based on heteromer identification technology (HIT).

It was also under development for IgA nephropathy, acute respiratory distress syndrome (ARDS) secondary to COVID -19 disease and diabetic retinopathy.

Dimerix overview

Dimerix is a bio-pharmaceutical company. The company conducts research and develops new therapies for diseases with unmet medical needs. Dimerix characterizes complex interactions between receptors, and it develops pharmaceutical products using Receptor Heteromer Investigation Technology. Its pipeline product includes DMX-200 for Covid, DMX-200 for Kidney Disease, DMX-700 for COPD. Dimerix conducts clinical trials for patients with diabetic kidney disease (DKD) and focal segmental glomerulosclerosis (FSGS). It’s Receptor-HIT technology helps in providing complex interactions between receptors and also helps in developing pharmaceutical products. The company operates through its subsidiary, Dimerix Biosciences Pty Ltd. Dimerix is headquartered in Fitzroy, Victoria, Australia.

Quick View Propagermanium LOA Data